BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

Corporate Breaking News

Home : BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

Jan 28 2021	BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients
LUND, Sweden, Jan. 28, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces positive interim results from...


Source:https://www.prnewswire.com:443/news-releases/bioinvent-phase-iiia-data-suggest-bi-1206-restores-activity-of-rituximab-in-relapsed-non-hodgkins-lymphoma-patients-301216922.html

Related News
» GAC Group achieves breakthrough in graphene-based fast-charging battery technology, vehicle model Aion V equipped with the new battery to start production in September » Omixon y SeqOnce Biosciences amplían AzureSeq-200 CE One-step RT-qPCR para detectar SARS-CoV-2 N501Y